Cereno Scientific participates in the Nordic-American Healthcare Conference 2023 (NAHC) in New York City
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that the company will participate at the Nordic-American Healthcare Conference 2023 (NAHC) on December 6-7, 2023, in New York City, US. The event is presented by DNB//Back Bay, Nasdaq, Innovation Norway, and Business Sweden.
Sten R. Sörensen, CEO, will attend the 8th Annual Conference NAHC 2023 in New York City. The event takes place over two days in New York City, and is an invitation-only event. NAHC brings together leading Nordic biotechnology, co-tech and health technology companies and investors, partners and business development managers, together with an outstanding network of private and public sector contributors – all committed to promoting cooperation between the US and the Nordic health service. NAHC is a network event where Nordic companies will participate together with the Nordic health clusters, trade organizations, global investors and US companies.
More information can be found on the event page: https://www.dnb.no/en/business/events/nordic-american-healthcare-conference
For further information, please contact:
Tove Bergenholt, Director IR & Communications
Email: tove.bergenholt@cerenoscientific.com
Phone: +46 732-366 246
Sten R. Sörensen, CEO
Email: sten.sorensen@cerenoscientific.com
Phone: +46 73-374 03 74
About Cereno Scientific AB
Cereno Scientific is a clinical-stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects, selected for prevention of thrombosis as target indication. In preclinical studies, it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. Thrombosis prevention in venous or arterial and cardiovascular disease has been selected as the first indication area for CS014. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.